In Silico Biology

#ADME / Tox #AI / data analytics / healthtech / informatics #Biochemistry #Biomarkers #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Toxicology

Balancing Quantity and Quality in Drug Discovery

Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microbiology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays for Assessment of Target Selectivity

Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug targets, each awaiting further validation, but having… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Predictive chemoinformatics applications to the pharmaceutical industry

Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development

By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Pharmacogenomics #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Chemical microarrays – The drug discovery superhighway

Chemical microarrays - The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool of genomic data and countless unvalidated targets… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #In Silico Biology #Lead discovery #Oncology #Pharmacogenomics #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companiessq

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development & optimisation #Automation / robotics #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Pharmokinetics #Precision medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Silicon Technology and Pharmaceutics

Silicon Technology and Pharmaceutics by Professor Leigh T. Canham, Dr Roghieh S. Saffie, Stephen E. Connor and Dr Roger Aston The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as a whole. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Therapeutics

A Revolution in R&D – The managerial challenges

The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries; and perhaps healthcare delivery in general; are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Developing a new drug… Read More

#Archive

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Screening #Sequencing #Stem cells #System biology #Systems biology #Translational #Translational chemistry

The Industrialisation of Bioinformatics

The Industrialisation of Bioinformatics By Dr Alex Titomirov With the completion of the ‘draft’ sequence of the human genome predicting an estimate of 40,000-120,000 genes that describe us, the real work begins. The problem now is not lack of data but lack of tools to thoroughly analyse what we already… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Exploiting the fruits of the human genome – A strategic perspective

By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #In Silico Biology #Lead discovery #Regulatory #RNA #Therapeutics

Target discovery and drug design: extracting the value from genomics

By Professor Ken Powell, Deputy Director, Wolfson Institute for Biomedical Research Pharmaceutical research and development is changing. The old model of drug discovery, based on a combination of imprecise candidate generation and broad physiological screens, has given way to more specific and intelligent approaches to target identification and drug design. Read More

#Archive